Stock of the Day: How Analysts Feel About Intellia Therapeutics Inc After Reaching All-Time Low?

Stock of the Day: How Analysts Feel About Intellia Therapeutics Inc After Reaching All Time Low?

The stock of Intellia Therapeutics Inc (NASDAQ:NTLA) reached all time low today, Oct, 5 and still has $14.92 target or 9.00% below today’s $16.40 share price. This indicates more downside for the $583.25M company. This technical setup was reported by Barchart.com. If the $14.92 PT is reached, the company will be worth $52.49M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. About 68,645 shares traded hands. Intellia Therapeutics Inc (NASDAQ:NTLA) has risen 6.00% since September 5, 2016 and is uptrending. It has underperformed by 2.26% the S&P500.

Analysts await Intellia Therapeutics Inc (NASDAQ:NTLA) to report earnings on November, 3. After $-0.36 actual earnings per share reported by Intellia Therapeutics Inc for the previous quarter, Wall Street now forecasts -41.67% EPS growth.

Intellia Therapeutics Inc (NASDAQ:NTLA) Ratings Coverage

Out of 4 analysts covering Intellia Therapeutics (NASDAQ:NTLA), 4 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Intellia Therapeutics has been the topic of 5 analyst reports since May 31, 2016 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Tuesday, May 31 by Credit Suisse. The firm has “Outperform” rating by Wedbush given on Tuesday, May 31. The firm has “Hold” rating given on Tuesday, May 31 by Jefferies. The rating was upgraded by Jefferies to “Buy” on Friday, August 5. The company was upgraded on Friday, August 5 by Leerink Swann.

According to Zacks Investment Research, “Intellia Therapeutics, Inc. is a genome editing company focused on the development of curative therapeutics using a biological tool, CRISPR/Cas9 system. Intellia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.”

More news for Intellia Therapeutics Inc (NASDAQ:NTLA) were recently published by: Marketwatch.com, which released: “/quotes/zigman/3870025/realtime” on May 06, 2016. Globenewswire.com‘s article titled: “Intellia Therapeutics to Present at September Investor Healthcare Conferences” and published on September 01, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Leave a Comment